a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients
- First Posted Date
- 2011-05-26
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2017
- Registration Number
- NCT01361009
- Locations
- 🇨🇳
Boehringer Ingelheim Investigational Site 52, Suzhou, China
🇨🇳Boehringer Ingelheim Investigational Site 57, Beijing, China
🇨🇳Boehringer Ingelheim Investigational Site 60, Beijing, China
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 678
- Registration Number
- NCT01358864
- Locations
- 🇺🇸
1220.7.0085 Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, United States
🇺🇸1220.7.0087 Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, United States
🇨🇦1220.7.1006 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: Micamlo
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1157
- Registration Number
- NCT01353274
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site 37, Hitachiota, Japan
🇯🇵Boehringer Ingelheim Investigational Site 199, Akaiwa, Japan
🇯🇵Boehringer Ingelheim Investigational Site 25, Akita, Japan
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT01348165
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
- Conditions
- Neoplasms
- Interventions
- Drug: Volasertib, low dose, d1q3wDrug: Volasertib, middle dose, d1q3wDrug: Volasertib, high dose, d1q3w
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT01348347
- Locations
- 🇯🇵
1230.15.001 National Cancer Center Hospital,, Chuo-ku, Tokyo, Japan
Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers
- Conditions
- Healthy
- Interventions
- Drug: BI 207127 NA (low dose)Drug: Matching placebo (low dose)Drug: BI 207127 NA (medium dose)Drug: Matching placebo (medium dose)Drug: BI 207127 NA (high dose)Drug: Matching placebo (high dose)
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT01347086
- Locations
- 🇰🇷
1241.8.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
- First Posted Date
- 2011-05-03
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01346540
- Locations
- 🇳🇱
1199.82.3102 Boehringer Ingelheim Investigational Site, Maastricht, Netherlands
🇪🇸1199.82.3406 Boehringer Ingelheim Investigational Site, Madrid, Spain
🇪🇸1199.82.3410 Boehringer Ingelheim Investigational Site, Málaga, Spain
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 617
- Registration Number
- NCT01345669
- Locations
- 🇧🇷
1200.131.05555 Boehringer Ingelheim Investigational Site, Jau, Brazil
🇦🇺1200.131.06151 Boehringer Ingelheim Investigational Site, Wooloongabba, Queensland, Australia
🇦🇷1200.131.05451 Boehringer Ingelheim Investigational Site, Ciudad Autonoma de Bs As, Argentina
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
- Conditions
- Head and Neck NeoplasmsCarcinoma, Squamous Cell
- Interventions
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 483
- Registration Number
- NCT01345682
- Locations
- 🇯🇵
1200.43.08111 Boehringer Ingelheim Investigational Site, Hyogo, Akashi, Japan
🇯🇵1200.43.08107 Boehringer Ingelheim Investigational Site, Hyogo, Kobe, Japan
🇫🇷1200.43.03303 Boehringer Ingelheim Investigational Site, Lille Cedex, France
Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT01344629
- Locations
- 🇯🇵
1235.28.001 Boehringer Ingelheim Investigational Site, Kumamoto, Kumamoto, Japan